title: Effect of endothelin-1 on corticosteroid secretion by the frog adrenal gland is mediated by an endothelinA receptor.
abstract: We have previously reported that endothelin-1 (ET-1) stimulates the in vitro secretion of corticosterone and aldosterone from the adrenal gland of the frog Rana ridibunda. The aim of the present study was to investigate the pharmacological profile of the endothelin receptor subtype involved in the corticotropic effect of ET-1. The mixed ET(A)/ET(B) receptor antagonist Ro 47-0203 (10(-5) M) totally blocked the stimulatory effect of ET-1 (5 x 10(-9) M) on corticosterone and aldosterone secretion. The action of ET-1 was also inhibited by the selective ET(A) receptor antagonist BQ-485 (10(-7) M). In contrast, the selective ET(B) receptor antagonist IRL 1038 (10(-6) M) did not affect the response of the frog adrenal gland to ET-1. In addition, the selective ET(B) receptor agonist IRL 1620 (10(-6) M) did not mimic the stimulatory effect of ET-1. The high affinity ET(C) receptor agonist endothelin-3 (ET-3) stimulated corticosteroid secretion, but was 400 times less potent than ET-1. Moreover, the action of ET-3 was also blocked by BQ-485 (10(-7) M). These data indicate that the stimulatory effects of ET-1 and ET-3 on corticosteroid secretion by the frog adrenal gland are mediated by an ET(A) receptor subtype.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale (INSERM U413), Unité Affiliée au Centre National de la Recherche Scientifique (UA CNRS), University of Rouen, France.
authors.forename: F
authors.initials: F
authors.lastname: Cartier
authors.forename: I
authors.initials: I
authors.lastname: Remy-Jouet
authors.forename: A
authors.initials: A
authors.lastname: Fournier
authors.forename: H
authors.initials: H
authors.lastname: Vaudry
authors.forename: C
authors.initials: C
authors.lastname: Delarue
mesh_terms: D000305:Adrenal Cortex Hormones / Q000378:metabolism*; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D000450:Aldosterone / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001381:Azepines / Q000494:pharmacology; D000077300:Bosentan; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology* / Q000502:physiology; D019334:Endothelin-3 / Q000494:pharmacology; D016232:Endothelins / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D011863:Radioimmunoassay; D011895:Rana ridibunda; D017466:Receptors, Endothelin / Q000032:analysis / Q000502:physiology*; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D001381:Azepines; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D019334:Endothelin-3; D016232:Endothelins; D009842:Oligopeptides; D010446:Peptide Fragments; D017466:Receptors, Endothelin; D013449:Sulfonamides; C074308:sovateltide; C083116:BQ 485; C077420:Cys(11)-Cys(15)-endothelin-1 (11-21); D000450:Aldosterone; D000077300:Bosentan